Intellia Therapeutics, Inc.

Ownership Transactions Reported by 20 Insiders

Symbol
NTLA on Nasdaq
Location
40 Erie Street, Suite 130, Cambridge, MA

Insiders trading volume in the past year

Intellia Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
John M. Leonard President and CEO, Director $12.2M -$327K -2.61% Jan 3, 2025
Glenn Goddard EVP, Chief Financial Officer $2.11M Mar 1, 2024
Fred E. Cohen Director $1.63M Jun 12, 2024
Edward J. Dulac III EVP, Chief Financial Officer $1.52M Jul 22, 2024
David Lebwohl EVP, Chief Medical Officer $1.07M -$116K -9.83% Jan 3, 2025
Laura Sepp-Lorenzino EVP, Chief Scientific Officer $943K -$109K -10.4% Jan 3, 2025
James Basta EVP, General Counsel $907K -$162K -15.1% Jan 3, 2025
William Chase Director $881K Jun 12, 2024
Birgit C. Schultes EVP, Chief Scientific Officer $824K Jan 13, 2025
Georgia Keresty Director $788K Jun 12, 2024
Eliana Clark EVP, Chief Technical Officer $780K -$126K -13.9% Jan 2, 2025
Derek Hicks EVP, Chief Business Officer $729K -$79.2K -9.8% Jan 3, 2025
Jesse Goodman Director $642K Jun 12, 2024
Michael P. Dube VP, Chief Accounting Officer $556K -$55K -9% Jan 3, 2025
Brian Goff Director $508K Jun 13, 2024
Frank Verwiel Director $449K -$37.6K -7.74% Jun 17, 2024
Caroline Dorsa Director $373K Jun 14, 2022
John F. Crowley Director $344K Jun 14, 2023
Jean Francois Formela Director $214K Jun 14, 2022
Muna Bhanji Director $194K -$2.64K -1.34% Jan 29, 2025

Recent Insider Transactions by Companies or Individuals for Intellia Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.